You are here:

NICE
NICE Guidance
Conditions and diseases
Cancer
Metastases

Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma

Technology appraisal guidance
Reference number: TA268
Published: 12 December 2012

Guidance
Tools and resources
Information for the public
History

Melanoma (stage III or IV) - ipilimumab: comments on the ACD received from the public through the NICE website

Melanoma (stage III or IV) - ipilimumab: comments on the ACD received from the public through the NICE website
Melanoma (stage III or IV) - ipilimumab: MP letters batch 1
Melanoma (stage III or IV) - ipilimumab: MP letters batch 2
Melanoma (stage III or IV) - ipilimumab: MP letters batch 3
Melanoma (stage III or IV) - ipilimumab: parliamentry report

This page was last updated: 01 November 2012